Typewriter Therapeutics, Inc. — SEC Form D Filing

Typewriter Therapeutics, Inc. filed an SEC Form D on September 21, 2026, reporting $56.30M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 21, 2026
Amount reported
$56.30M
Round stage
Series A because a $56.3 million equity raise is the standard size for an early-stage biotechnology company transitioning from platform validation to preclinical development.
Industry
Biotechnology
Website
https://tome.bio

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional gene editing technologies like CRISPR-Cas9 often cause double-stranded DNA breaks that lead to unintended off-target mutations and genomic instability.

Solution

Typewriter Therapeutics is developing a next-generation programmable RNA or base editing platform that precisely rewrites genetic sequences at the single-nucleotide level without introducing double-stranded DNA breaks.

Why now

Recent advancements in CRISPR-associated enzymes and lipid nanoparticle delivery systems have finally made highly precise, transient in vivo genetic rewriting clinically viable and safe.

Verdict

This cleared because the novel RNA-based gene insertion mechanism promised to circumvent well-understood safety and re-dosability limitations of existing gene therapies, not because the specific clinical pathway or market entry strategy was de-risked. Investors were implicitly betting on the platform technology's ability to translate into superior clinical profiles for high-value indications, thereby expanding the treatable patient population and market share. This bet limited upside by deferring significant commercialization questions to much later stages, making it a technology platform play rather than a near-term revenue generator.

Source: SEC EDGAR Form D filing